Themis Medicare Ltd Hits Intraday High with 7.03% Surge on 3 Feb 2026

Intraday Trading Highlights

The stock opened sharply higher with a gap-up of 9.59%, signalling strong buying interest from the outset. Throughout the trading session, Themis Medicare maintained upward momentum, reaching an intraday peak of Rs 84.99, reflecting a 9.59% gain from its previous close. This marks a notable reversal after two consecutive days of declines, underscoring a shift in trading sentiment.

Despite the strong intraday gains, the stock’s price remains positioned above its 5-day moving average but below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that while short-term momentum has improved, longer-term trends remain subdued.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector, to which Themis Medicare belongs, advanced by 2.81% on the day, with Themis Medicare outperforming the sector by 4.19%. This outperformance highlights the stock’s relative strength within its industry group.

In contrast, the broader market experienced a volatile session. The Sensex opened with a substantial gap-up of 3,656.74 points but lost momentum to close down by 1,377.65 points, settling at 83,945.55, a decline of 2.79%. The index remains 2.64% below its 52-week high of 86,159.02. Notably, the Sensex is trading below its 50-day moving average, although the 50-day average itself remains above the 200-day moving average, suggesting mixed technical signals.

Mega-cap stocks led the market’s gains earlier in the session, but the overall market pullback contrasts with Themis Medicare’s strong intraday performance, emphasising the stock’s distinct trading dynamics today.

Performance Metrics and Trend Analysis

Examining Themis Medicare’s recent performance reveals a mixed picture. The stock’s one-day gain of 7.03% notably outpaces the Sensex’s 2.80% rise on the same day. Over the past week, Themis Medicare has gained 6.34%, again exceeding the Sensex’s 2.56% increase.

However, longer-term trends remain challenging. The stock has declined 18.55% over the past month and 33.68% over three months, compared with the Sensex’s respective declines of 2.11% and 0.03%. Year-to-date, Themis Medicare is down 17.54%, while the Sensex has fallen 1.49%. Over one year, the stock has dropped 62.49%, contrasting with the Sensex’s 8.76% gain.

Over three years, Themis Medicare’s performance is negative at -34.84%, whereas the Sensex has appreciated 37.98%. Despite this, the stock has delivered a 150.45% return over five years, outperforming the Sensex’s 67.05% gain in the same period. Over a decade, Themis Medicare’s 135.19% return trails the Sensex’s 246.57% advance.

Mojo Score and Market Capitalisation

Themis Medicare currently holds a Mojo Score of 17.0, with a Mojo Grade of Strong Sell as of 1 Feb 2025, an upgrade from its previous Sell rating. The company’s market capitalisation grade stands at 3, reflecting its relative size and liquidity within the Pharmaceuticals & Biotechnology sector.

This grading indicates a cautious stance on the stock’s overall quality and market standing despite the recent intraday strength.

Summary of Trading Action

Themis Medicare’s strong intraday performance on 3 Feb 2026 stands out in a market environment where the broader indices faced pressure after an initial surge. The stock’s ability to open with a significant gap-up and sustain gains throughout the session highlights active trading interest and a positive shift in short-term momentum.

While the stock remains below several key moving averages, the break above the 5-day average suggests a potential short-term technical improvement. The outperformance relative to both the Pharmaceuticals & Biotechnology sector and the Sensex underscores the stock’s distinct trading behaviour today.

Investors and market participants will likely continue to monitor Themis Medicare’s price action closely in the coming sessions to assess whether this intraday strength can be sustained or extended.

Market Overview

The broader market’s mixed session, with the Sensex retreating after a strong opening, reflects ongoing volatility and selective sectoral strength. Mega-cap stocks initially led gains, but the overall market pullback contrasts with Themis Medicare’s notable intraday surge, emphasising the stock’s unique performance within the current market context.

Conclusion

Themis Medicare Ltd’s 7.03% intraday gain and Rs 84.99 peak price on 3 Feb 2026 represent a significant rebound after recent declines. The stock’s outperformance relative to its sector and the Sensex, combined with its gap-up opening and sustained buying interest, mark it as a key focus within the Pharmaceuticals & Biotechnology space for this trading session.

Unlock special upgrade rates for a limited period. Start Saving Now →